论文部分内容阅读
目的:观察并讨论缬沙坦联合硝苯地平缓释片治疗原发性高血压临床疗效分析。方法:选取2010年1月~2014年12月来我院治疗的58例原发性高血压患者进行回顾性分析,随机分成两组,即观察组与对照组。对照组患者单纯采用硝苯地平缓释片进行治疗,观察组患者在对照组基础上联合缬沙坦进行治疗,观察两组患者在经过各自治疗后的临床疗效及不良反应。结果:经比较得知,缬沙坦联合硝苯地平缓释片治疗的观察组患者在疗效方面明显好于对照组,两组患者的临床疗效存在显著差异(P<0.05),具有统计学意义。结论:缬沙坦联合硝苯地平缓释片治疗原发性高血压的临床疗效可靠,不良反应少,可加大临床的推广及应用。
Objective: To observe and discuss the clinical efficacy of valsartan combined with nifedipine sustained-release tablets in the treatment of essential hypertension. Methods: Fifty-eight patients with essential hypertension who were treated in our hospital from January 2010 to December 2014 were retrospectively analyzed and randomly divided into two groups: observation group and control group. Patients in the control group were treated with nifedipine sustained-release tablets only. The patients in the observation group were treated with valsartan on the basis of the control group, and the clinical efficacy and adverse reactions of the two groups after treatment were observed. Results: Compared with the control group, the observation group treated with valsartan combined with nifedipine sustained-release tablets showed significantly better curative effect than the control group (P <0.05), with statistical significance . Conclusion: Valsartan combined with nifedipine sustained-release tablets in the treatment of essential hypertension with reliable clinical efficacy, fewer adverse reactions, can increase the clinical promotion and application.